Company Description
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine.
The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900.
Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Teofilo David Raad MBA |
Contact Details
Address: 36 Crosby Drive, Suite 100 Bedford, Massachusetts 01730 United States | |
| Phone | (781) 357-2333 |
| Website | pulmatrix.com |
Stock Details
| Ticker Symbol | PULM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574235 |
| CUSIP Number | 74584P301 |
| ISIN Number | US74584P3010 |
| Employer ID | 46-1821392 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Teofilo David Raad MBA | President, Chief Executive Officer and Director |
| Peter Ludlum CMA, MBA | Interim Chief Financial Officer and Principal Accounting and Financial Officer |
| Dr. Alexander M. Klibanov Ph.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | 424B3 | Prospectus |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Jan 8, 2024 | 8-K | Current Report |
| Jan 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Nov 9, 2023 | 8-K | Current Report |
| Aug 10, 2023 | 10-Q | Quarterly Report |